Abstract
With great interest, we read the paper “Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis” (by Chen PQ et al.) [1], which has reached important conclusions about the relationship between polymorphisms in interleukin (IL)-4/IL-13 pathway genes and glioma risk. Through quantitative analysis, the meta-analysis found no association between IL-4/IL-13 pathway genetic polymorphisms and glioma risk (Chen et al. in Tumor Biol 36:121–127, 2015). The meta-analysis is the most comprehensive study of polymorphisms in the IL-4/IL-13 pathway and glioma risk. Nevertheless, some deficiencies still exist in this meta-analysis that we would like to raise.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Chen PQ, Chen C, Luo C, et al. Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis. Tumor Biol. 2015;36:121–7.
Al-Moundhri MS, Al-Nabhani M, Al-Bahrani B, Burney IA, AlMadhani A, Ganguly SS, et al. Interleukin-1beta gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms and gastric cancer risk in an Omani Arab population. Gastric Cancer. 2006;9(4):284–90.
Gao LB, Pan XM, Li LJ, Liang WB, Zhu Y, Zhang LS, et al. RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies. Breast Cancer Res Treat. 2011;125(3):827–35.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
None
Rights and permissions
About this article
Cite this article
Wang, TT., Li, JM. & Zhou, D. Note of the methodological flaws in the paper entitled “Polymorphisms in IL-4/IL-13 pathway genes and glioma risk: an updated meta-analysis”. Tumor Biol. 37, 199–200 (2016). https://doi.org/10.1007/s13277-015-4570-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-015-4570-0